From May 10th to 12th, RocRock Biotech participated in the STINT-NSFC Network "Transcriptome complexity in human disease" closed-door symposium held at Engelsholms Slott Castle in Sweden, where they engaged in in-depth discussions on topics such as the complexity of human disease transcriptomes. The main institutions attending this symposium included SciLifeLab Sweden, Karolinska Institutet, Stockholm University, Huazhong University of Science and Technology, and Lingang Lab, among others.

The three-day symposium gathered numerous experts, researchers, and representatives from companies in the global biotechnology

 and cell therapy fields, focusing on the complexities of human disease transcriptomes. During the discussions, RocRock Biotech and 

Karolinska Institutet announced the approval of the Bluesky project, which will collaborate on the development of CAR-M cell

 therapies. Building on their previous successful cooperation, RocRock Biotech and Karolinska Institutet will also jointly advance the 

large-scale screening project for the CAR-M phagocytosis platform. This deep collaboration undoubtedly brings more hope to global

 solid tumor patients and injects new possibilities into the future of cell therapy, promoting continuous progress in human health.

As of now, CAR-T therapy has demonstrated significant efficacy in the treatment of hematological malignancies, while cell therapies 

for solid tumors are still under exploration. In recent years, macrophages have gained favor among developers both domestically and

 internationally for their unique ability to kill and penetrate tumors in the field of solid tumor treatment. Dr. Yin Xiushan, co-founder

 of RocRock Biotech, discussed the company's novel CAR-M viral delivery platform and shared insights on the future of cell therapy as 

a leading global CAR-M enterprise. CAR-M has broad market prospects and is expected to provide patients with more precise and 

effective treatment options. Dr. Yin also stated that Kunshi Biotech will continue to increase its R&D investment to offer more

 innovative cell therapy products for patients worldwide.

The three-day STINT-NSFC closed-door symposium undoubtedly injected new vitality into the academic and industrial communities worldwide that are focused on the complexity of human disease transcriptomes. As an innovative technology enterprise, RocRock Biotech insists on being at the forefront of targeted drug development for solid tumors, committed to bringing two innovative drugs to market successfully within 5-6 years, and tirelessly working towards extending the lifespan of every solid tumor patient by 24 years.